A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
=== Tourne === Compared to malic and citric acids, tartaric acid is usually considered microbiologically stable. However, some species of Lactobacillus (particularly L. brevis and L. plantarum) have the potential to degrade tartaric acid in wine, reducing a wine's total acidity by 3-50%. French winemakers had long observed this phenomenon and called it tourne (meaning "turn to brown") in reference to the color change that can occur in the wine at the same time likely due to other processes at work in addition to the tartaric loss. While Lactobacillus is the most common culprit of tourne, some species of the spoilage film yeast Candida can also metabolize tartaric acid.
A lower-end product includes salt, hydrogenated fat, monosodium glutamate, flavor enhancers, and flavors. It is labelled as "beef flavor" without beef. A mid-end product typically combines cheaper sources of flavor with actual meat/bone/vegetable (usually first cooked into an extract) and/or animal fat. For example, Maggi bouillon cubes are manufactured from iodized salt, hydrogenated palm oil, wheat flour, flavor enhancers (monosodium glutamate, disodium inosinate, disodium guanylate), chicken fat, chicken meat, sugar, caramel, yeast extract, onion, spices (turmeric, white pepper, coriander), and parsley. A high-end product typically mainly rely on meat/bone/vegetable (usually extracted) for the meaty flavor and savoriness, such as described in a 2004 patent. As an example, "Better than Bouillion" is made from roasted chicken, salt, sugar, maltodextrin, chicken stock, yeast extract, onion powder, garlic powder, tumeric, and flavoring.
=== Video games === Half-Life (1998) Half-Life 2 (2004) Half-Life 2: Episode One (2006) Half-Life 2: Episode Two (2007) Portal (2007) Counter-Strike: Global Offensive (additional music, 2015) Vanishing Realms: Rite of Steel (2016-2019)
The epoxy cycle of ethylene oxide is an almost regular triangle with bond angles of about 60° and a significant angular strain corresponding to the energy of 105 kJ/mol. For comparison, in alcohols the C–O–H angle is about 110°; in ethers, the C–O–C angle is 120°. The moment of inertia about each of the principal axes are IA = 32.921×10−40 g·cm2, IB = 37.926×10−40 g·cm2 and IC = 59.510×10−40 g·cm2. The relative instability of the carbon-oxygen bonds in the molecule is revealed by the comparison in the table of the energy required to break two C–O bonds in the ethylene oxide or one C–O bond in ethanol and dimethyl ether:
Sources: en.wikipedia.org
The United States of America stayed neutral, but some Americans were eager to participate. Early in the war Lord Roberts cabled Major Frederick Russell Burnham, a veteran of both Matabele wars but then prospecting in the Klondike, to serve on his personal staff as Chief of Scouts. Burnham went on to receive the highest awards of any American who served in the war. American mercenaries participated on both sides. Portugal had considerable dealings with the South African Republic through Portuguese Mozambique. The war broke out while Portugal was engaged in its own pacification campaigns in Africa and after the 1890 British Ultimatum Portuguese public opinion was highly favourable to the Boers, but the Portuguese government chose not to hostilize the United Kingdom. Instead it took the opportunity to mend bilateral relations and reaffirm the Anglo-Portuguese alliance through the signing of the Second Treaty of Windsor, by which Britain recognized Portuguese claims in Africa and reaffirmed its pledge to help defend Portugal as well as its overseas empire against all enemies "future and present", in exchange for Portugal not declaring neutrality and providing aid against the Boers, namely by blocking the passage of weapons and ammunitions through its territory and allowing Britain the use of its port facilities. In 1900, 700 Boers crossed into Mozambique to seek refuge, but this group soon grew to 1400-2500. 700-900 were transported to Caldas da Rainha in Portugal, where they were kept until the end of the war.
==== External auditory canal ==== Barotrauma can occur in the external auditory canal if it is blocked by cerumen, exostoses, a tight-fitting diving suit hood or earplugs, which create an airtight, air-filled space between the eardrum and the blockage. On descent, a pressure differential develops between the ambient water and the interior of this space, and this can cause swelling and haemorrhagic blistering of the canal. Treatment is usually analgesics and topical steroid eardrops. Complications may include local infection. This form of barotrauma is usually easily avoided.
posttraumatic osteoarthritis As mentioned, damage to the chondral surface of the joint has a high risk of posttraumatic arthritis if the joint is not returned to native alignment. malunion When bones are not set back into close to native alignment there is a risk of healing in a malformed position. nonunion If there is not adequate blood flow to provide healing factors to the fracture or there is too much movement at the area of injury there is risk of not healing. Diabetes, smoking, and peripheral vascular disease increase risk of nonunion. avascular necrosis When fractured, blood supply can be disrupted to certain bones or areas of bone causing that portion of bone to die and necrose. Examples include the femoral head of the hip joint and the scaphoid of the wrist. joint stiffness and pain Damaged soft tissue leads to build up of scar tissue which can make joints stiff and painful.
Along the western coast of South America, water near the ocean surface is pushed westward due to the combination of the trade winds and the Coriolis effect. This process is known as Ekman transport. Colder water from deeper in the ocean rises along the continental margin to replace the near-surface water. This process cools the East Pacific because the thermocline is closer to the ocean surface, leaving relatively little separation between the deeper cold water and the ocean surface. The northward-flowing Humboldt Current carries colder water from the Southern Ocean to the tropics in the East Pacific. The combination of the Humboldt Current and upwelling maintains an area of cooler ocean waters off the coast of Peru. The West Pacific lacks a cold ocean current and has less upwelling as the trade winds are usually weaker than in the East Pacific, allowing the West Pacific to reach higher temperatures. These warmer waters provide energy for the upward movement of air. As a result, the warm West Pacific has, on average, more cloud and rain than the cool East Pacific. ENSO describes a quasi-periodic change of both oceanic and atmospheric conditions over the tropical Pacific Ocean. These changes affect weather patterns across much of the Earth. The tropical Pacific is said to be in one of three states of ENSO (also called "phases") depending on the atmospheric and oceanic conditions. When the tropical Pacific roughly reflects the average conditions, the state of ENSO is said to be in the neutral phase.
People who receive atoltivimab/maftivimab/odesivimab should avoid the concurrent administration of a live vaccine due to the treatment's potential to inhibit replication of a live vaccine virus indicated for prevention of Ebola virus infection and possibly reduce the vaccine's efficacy. Atoltivimab/maftivimab/odesivimab is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies. The three antibodies target the glycoprotein that is on the surface of the Ebola virus. This glycoprotein normally attaches to the cell via a receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The antibodies can bind to it simultaneously at three different locations and block attachment and entry of the virus. This combination drug targets the Zaire species of Ebola virus. The Sudan and Bundibugyo strains have also caused outbreaks, and it is unlikely that it would be effective against these strains.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.